Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 684 of 5804
-
New hope for hard-to-treat esophageal cancer?
Disease control OngoingThis multi-center, open label Phase II clinical study is performed in patients with relapsed and metastatic esophageal squamous cell carcinoma progressed on prior PD-1/L1 antibody with or without chemotherapy. This study is investigating the safety and efficacy of SI-B001 at opti…
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Gene-Targeted obesity drug shows promise in phase 3 trial
Disease control OngoingThe protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: * POMC or PCSK1 (Sub-study 035a) * LEPR (Sub-…
Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New cocktail of drugs takes on tough pancreatic cancer
Disease control OngoingThe proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a single injection repair arthritic knees?
Disease control CompletedA randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the efficacy and safety of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrow…
Phase: PHASE3 • Sponsor: Kolon TissueGene, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New combo therapy shows promise for hard-to-treat stomach and bowel cancers
Disease control CompletedThe study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years and older with advanced and metastatic gastrointesti…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
One-Time gene shot could cut eye injections for wet AMD
Disease control Recruiting nowPhase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
Phase: PHASE1, PHASE2 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could a new drug replace steroids for lupus kidney patients?
Disease control Recruiting nowThis is a randomised, open label, controlled non-inferiority phase III multicentre trial. As primary objective, the study aims to demonstrate that a regimen free of additional oral corticosteroids but with obinutuzumab (and MMF) is non-inferior to a regimen based on oral cortico…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New device aims to limit heart damage during heart attacks
Disease control OngoingThis study is designed to compare the safety and effectiveness of blood clot (thrombus) removal in subjects presenting with ST-segment elevation myocardial infarction (STEMI) with the enVast coronary system versus conventional intervention.
Phase: NA • Sponsor: Vesalio • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy aims to ease swallowing in advanced esophageal cancer
Disease control Recruiting nowThe purpose of this study is to investigate the effects of the addition of the stereotactic body radiotherapy and durvalumab to a well tolerated 2 week chemotherapy and radiation treatment regimen in people with esophageal cancer that is locally advanced or has spread to another …
Phase: PHASE2 • Sponsor: Australasian Gastro-Intestinal Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New pill shows promise for HER2 lung cancer in early trial
Disease control Recruiting nowThis is a multicenter, single-arm phase II clinical study to evaluate the safety and efficacy of pyrotinib maleate as a first-line treatment for HER2-mutated or amplified non-small cell lung cancer. Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irrevers…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New combo therapy aims to boost immune attack on deadly brain cancer
Disease control CompletedBackground: Glioblastoma (GBM) is a type of malignant glioma. These cancers are nearly always fatal. People who develop these cancers get aggressive treatments. But the tumors almost always recur. Researchers want to study people with newly diagnosed disease to learn more. Obje…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowBackground: A new cancer treatment takes a person s own T cells, modifies them in a laboratory so they can better fight cancer cells, and then gives them back to the person. Researchers want to see if this treatment can help people with a certain types of cancer. Objective: To…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for tough lung cancers: experimental drug combo tested
Disease control OngoingThis multi-center, open label phase II clinical study is performed in patients with locally advanced or metastatic EGFR wild-type ALK wild-type non-small cell lung cancer progressed on prior anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and e…
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental stem cell transplant could reduce toxic side effects for fanconi anemia patients
Disease control Recruiting nowThe objective of this clinical trial is to develop a cell therapy for Fanconi Anemia which enables enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting depleted stem cells from a donor with and without using an experimental antibody trea…
Phase: PHASE1, PHASE2 • Sponsor: Porteus, Matthew, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on sarcoma in new combo trial
Disease control Recruiting nowThe purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this therapy might help patients with sarcoma. Another g…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could waiting on radiation save your brain? new trial investigates
Disease control Recruiting nowBecause of their prolonged survival, patients with 1p/19q-codeleted low-grade oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration. We make the hypothesis that withholding radiotherapy until tumor progression could reduce the risk of neurocognitive…
Phase: PHASE3 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
5-Day brain zaps could lift depression and OCD faster than ever
Symptom relief Recruiting nowRepetitive transcranial magnetic stimulation (rTMS) is a FDA-approved treatment for depression and Obsessive Compulsive Disorder (OCD). The goal of the study is to learn how to optimize the treatment to improve symptoms of depression and OCD. This research project will test a new…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New pill could help patients with rare blood disorder
Disease control OngoingAll participants will receive rilzabrutinib orally. The screening period is up to 28 days, followed by a treatment period of 24 weeks for Part A. Participants who complete Part A and are deemed eligible for Part B can continue in the Core Part B period followed by an Extended Par…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a simple pill replace the shot for syphilis?
⭐️ CURE ⭐️ CompletedAccording to European and US Centers for Disease Control and Prevention (CDC) guidelines, the recommended treatment for uncomplicated early syphilis in adults (i.e. primary, secondary and early latent) is a single intramuscular injection of 2.4 million units of benzathine benzylp…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 07:58 UTC
-
New drug aims to supercharge immune system against HPV throat cancer
Disease control Recruiting nowThis is a phase 2 trial to assess the safety and tolerability of three schedules of CUE-101 administered in the neoadjuvant phase before standard of care (SOC) therapy to treatment naïve, HLA-A\*0201 positive patients with newly diagnosed, locally advanced HPV16+ oropharyngeal sq…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC